Searched for
ADHISH PATIL
Aarti Drugs shares skyrocket over 19% on Q1 results and buyback announcementFurther, the board has approved a buyback not exceeding 6,65,000 lakh equity shares for an amount not exceeding Rs 59.85 crore. The buyback...- Forex policy does not impact our margins: Adhish Patil, CFO, Aarti Drugs"Our domestic sales have gone down by 18% in this quarter which is purely because of the GST transitioning. However, exports numbers showed...
- Demonetisation pushed domestic sales down but biz set to go up: Adhish Patil, CFO, Aarti DrugsAdhish Patil, CFO, Aarti Drugs, in an interview with ET now revealed his company's future outlook
- Southeast Asia and Europe will be the key markets for us: Adhish Patil, Aarti Drugs“But India is going very strong and domestic growth is way higher than the export growth.”
- Will call FDA for re audit once consultants are confident for reinspect: Adhish Patil of Aarti DrugsThe thing is business things are looking good, in fact, the export market has started looking good in the second quarter so we hope that it...
- We have products in pipeline which look promising: Adhish Patil, Aarti Drugs"We will be submitting the queries of the EDQM, that the European authority for the anti-diabetic plant this week itself."
- Expecting audit report from third party on Palghar plant this week: Adhish Patil, Aarti Drugs CFOIn a chat with ET Now Adhish Patil, Aarti Drugs CFO, said that the company is expecting audit report from third party on Palghar plant this...
- Aarti Drugs plunges as Q4 results below Street estimatesShares of Aarti Drugs closed the day at Rs 687.50; down 6.78%. The stock slipped over 8.3 per cent in intraday trade.
- Expect next three years to be very good for us: Adhish Patil, Aarti DrugsWe had five DMS active from this particular plant. We got a warning letter back in August 2014. We have already sent four responses to the ...
Load More
